Terms: = Lung cancer AND MTCP1, C6_1B, 4515, ENSG00000214827, GS1-273L24_4 AND Treatment
30401 results:
1. Exploring the mechanism of 6-Methoxydihydrosanguinarine in the treatment of lung adenocarcinoma based on network pharmacology, molecular docking and experimental investigation.
Liu X; Ren Y; Qin S; Yang Z
BMC Complement Med Ther; 2024 May; 24(1):202. PubMed ID: 38783288
[TBL] [Abstract] [Full Text] [Related]
2. Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC.
Mao Z; Pang G; Huang X; Chen X; Wu J; Xu X; Teng Z; Tan Y; Wang P
BMC Pulm Med; 2024 May; 24(1):253. PubMed ID: 38783253
[TBL] [Abstract] [Full Text] [Related]
3. cancer treatment Before and After Physician-Pharmacy Integration.
Kanter GP; Ozluk P; Chi W; Fisch MJ; Debono D; Parikh RB; Jacobson M; Bekelman JE; DeVries A
JAMA Netw Open; 2024 May; 7(5):e2412998. PubMed ID: 38780938
[TBL] [Abstract] [Full Text] [Related]
4. The efficiency and safety of temozolomide and PD-1/L1 inhibitors in pretreated NSCLC with brain metastasis: a retrospective cohort.
Li X; Wu D; Tang J; Wu Y
J Cancer Res Clin Oncol; 2024 May; 150(5):271. PubMed ID: 38780840
[TBL] [Abstract] [Full Text] [Related]
5. Development and validation of a model for predicting upstage in minimally invasive lung adenocarcinoma in Chinese people.
Liao Y; Li Z; Song L; Xue Y; Chen X; Feng G
World J Surg Oncol; 2024 May; 22(1):135. PubMed ID: 38778366
[TBL] [Abstract] [Full Text] [Related]
6. 3,3'-((3,4,5-trifluoropHenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) inhibit lung cancer cell proliferation and migration.
Luo W; Chang G; Lin D; Xie H; Sun H; Li Z; Mo S; Wang R; Wang Y; Zheng Z
PLoS One; 2024; 19(5):e0303186. PubMed ID: 38776295
[TBL] [Abstract] [Full Text] [Related]
7. Assessment of Radiation Induced Pneumonitis and Pericarditis in Patients Undergoing Breast Conservative treatment Using Hypofractionated Simultaneous Integrated Boost Technique.
Sundaramoorthy S; Karunanidhi G; Pal P; C SV; Radhakrishnan H
Gulf J Oncolog; 2024 May; 1(45):15-29. PubMed ID: 38774929
[TBL] [Abstract] [Full Text] [Related]
8.
McMahon NP; Solanki A; Wang LG; Montaño AR; Jones JA; Samkoe KS; Tichauer KM; Gibbs SL
Theranostics; 2024; 14(7):2816-2834. PubMed ID: 38773974
[No Abstract] [Full Text] [Related]
9. The role of seven tumor-associated autoantibodies in the diagnosis, staging and treatment guidance of lung cancer.
Ma H; Wu T; Zhang Q; Ding Q
BMC Pulm Med; 2024 May; 24(1):250. PubMed ID: 38773432
[TBL] [Abstract] [Full Text] [Related]
10. Interventions for smoking cessation in hospitalised patients.
Streck JM; Rigotti NA; Livingstone-Banks J; Tindle HA; Clair C; Munafò MR; Sterling-Maisel C; Hartmann-Boyce J
Cochrane Database Syst Rev; 2024 May; 5(5):CD001837. PubMed ID: 38770804
[TBL] [Abstract] [Full Text] [Related]
11. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
[TBL] [Abstract] [Full Text] [Related]
12. Strategies to address recruitment to a randomised trial of surgical and non-surgical treatment for cancer: results from a complex recruitment intervention within the Mesothelioma and Radical Surgery 2 (MARS 2) study.
Mills N; Farrar N; Warnes B; Ashton KE; Harris R; Rogers CA; Lim E; Elliott D
BMJ Open; 2024 May; 14(5):e079108. PubMed ID: 38760029
[TBL] [Abstract] [Full Text] [Related]
13. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
Yin X; Liu X; Ren F; Meng X
Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
[TBL] [Abstract] [Full Text] [Related]
14. Clinic information, pathological, and imaging characteristics in 2 058 surgical patients with lung cancer from a single center.
Long B; Xiong Z; Liu S; Cheng Y; Li M; Liao W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Feb; 49(2):247-255. PubMed ID: 38755720
[TBL] [Abstract] [Full Text] [Related]
15. Non-Small Cell lung cancer, Version 4.2024.
Riely GJ; Wood DE; Ettinger DS; Aisner DL; Akerley W; Bauman JR; Bharat A; Bruno DS; Chang JY; Chirieac LR; DeCamp M; Desai AP; Dilling TJ; Dowell J; Durm GA; Gettinger S; Grotz TE; Gubens MA; Juloori A; Lackner RP; Lanuti M; Lin J; Loo BW; Lovly CM; Maldonado F; Massarelli E; Morgensztern D; Mullikin TC; Ng T; Owen D; Owen DH; Patel SP; Patil T; Polanco PM; Riess J; Shapiro TA; Singh AP; Stevenson J; Tam A; Tanvetyanon T; Yanagawa J; Yang SC; Yau E; Gregory KM; Hang L
J Natl Compr Canc Netw; 2024 May; 22(4):249-274. PubMed ID: 38754467
[TBL] [Abstract] [Full Text] [Related]
16. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
Salim N; Tumanova K; Popodko A; Libson E
JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
[TBL] [Abstract] [Full Text] [Related]
17. Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.
Chang GC; Shih JY; Yu CJ; Chao HS; Yang CT; Lin CC; Hung JY; Hsiao SY; Wang CC; Chian CF; Hsia TC; Chen YM
PLoS One; 2024; 19(5):e0303046. PubMed ID: 38753697
[TBL] [Abstract] [Full Text] [Related]
18. Evaluation of sex inequity in lung-cancer-specific survival.
Lærum D; Strand TE; Brustugun OT; Gallefoss F; Falk R; Durheim MT; Fjellbirkeland L
Acta Oncol; 2024 May; 63():343-350. PubMed ID: 38751329
[TBL] [Abstract] [Full Text] [Related]
19. Implications of GCLC in prognosis and immunity of lung adenocarcinoma and multi-omics regulation mechanisms.
Huang Z; Liang F; Wu J; Huang Z; Li Y; Huang X; Liu Z
BMC Pulm Med; 2024 May; 24(1):239. PubMed ID: 38750474
[TBL] [Abstract] [Full Text] [Related]
20. Erythema dyschromicum perstans-like eruptions induced by epidermal growth factor receptor inhibitors in patients with lung cancer.
Bang AS; Said JT; Hirner J; Rana J; Pugliese S; Wang JY; Zaba L; Zhao L; Doan L; Smith J; Kwong BY
Support Care Cancer; 2024 May; 32(6):354. PubMed ID: 38750379
[TBL] [Abstract] [Full Text] [Related]
[Next]
